You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

September 23, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

New type 2 diabetes drug approved by FDA

FDA has approved Trulicity (dulaglutide, Eli Lilly) to treat type 2 diabetes mellitus.
» Read about this once-weekly subcutaneous injection

Medications are the new battlefield and pharmacists are the best "recon" agents

The American Society of Consultant Pharmacists discuss in our Blog how pharmacists are best equipped to handle medication reconciliation in the medication battlefield.
» Read their discussion here

Continuing Education

MTM essentials for anticoagulant management in cardiovascular disease

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the pharmacological properties, safety and efficacy, and risk/benefit profile for the various anticoagulant medications used in cardiovascular diseases.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT10-VXP89.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Experience Brief: Femoral nerve block reduces hospital admissions, opioids in pediatrics

Femoral nerve block (FNB), an ultrasound-guided regional anesthesia, has cut the need for opioids, limited pain and sped up recovery in pediatric patients at Nationwide Children's Hospital in Columbus, Ohio. » See more

 

Related Articles

FDA approval given for new drug to treat obesity

Respiratory virus Enterovirus D68 hits hardest in kids with asthma

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group